AstraZeneca’s Andexxa May Continue Dangling In Accelerated Approval After Mixed Advisory Panel

 
• By Sarah Karlin-Smith
  
Three sets of legs dangling off platform overlooking mountains
The advisory committee outcome may leave AstraZeneca's Andexxa dangling in accelerated approval. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US Advisory Committees

More from United States